In Reply to “The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease”

Abstract

To the Editor, We would like to thank Dr. Kawada for appreciating our subgroup analysis to evaluate the safety and efficacy of tolvaptan in Japanese patients with autosomal dominant polycystic kidney disease (ADPKD). Dr. Kawada has suggested that one of our references regarding eGFR [1] is not consistent with the Chronic Kidney Disease Epidemiology… (More)
DOI: 10.1007/s10157-015-1154-7

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics